Re: [新聞] 藥華藥實施庫藏股擬買回3,200張

看板Stock作者oist77 (內心的吶喊)時間3年前 (2020/10/28 16:28)推噓7(7推 0噓 13→)

留言20則, 15人參與討論串2/4 (看更多)

ICC ruled in favor of AOP Orphan Pharmaceuticals AG in arbitration proceedings pertaining to BESREMi® (Ropeginterferon alpha-2b) https://reurl.cc/2gN424 On Tuesday, October 20, 2020 a Tribunal under the auspices of the International Chamber of Commerce (ICC) rendered its final award in an arbitral dispute between PharmaEssentia Corp. (hereinafter “PharmaEssentia” ) and AOP Orphan Pharmaceuticals AG (hereinafter “AOP Orphan”). AOP Orphan was awarded approximately EUR 143 million in damages. Vienna, October 27, 2020. After two and a half years of arbitration proceedings concerning BESREMi® (Ropeginterferon alfa-2b), the decision by the ICC Arbitral Tribunal has now been made. In 2017 PharmaEssentia had attempted to terminate the contractual agreement with AOP Orphan. The arbitral award states that the termination of the aforementioned contract was unjustified and thus that the license agreement remains in full force and effect. Consequently, AOP Orphan is entitled to payment of damages for project delays caused by PharmaEssentia, resulting in delays of the approval of the medicinal product for human use BESREMi® in Europe and delays in supply to patients affected by polycythaemia vera. On these grounds, the ICC has awarded AOP Orphan damages of a total of approximately EUR 143 million. Based on the above mentioned contract which has a territorial focus on Europe, AOP Orphan started the development of BESREMi® in 2009: Whereas PharmaEssentia supplied the active pharmaceutical ingredient, AOP Orphan completed the development of the drug product, conducted Phase I/II and Phase III clinical trials to verify the use of BESREMi® in patients with polycythaemia vera, and subsequently successfully submitted the dossier for approval by the European Medicines Agency (EMA). Furthermore, AOP Orphan has started and completed additional clinical trials in polycythaemia vera in a different patient risk group, and in chronic myeloid leukaemia and myelofibrosis under the context of the further overall development program in order to fully exploit the commercial value of BESREMi®. “We are relieved that the ICC ruling compensates AOP Orphan now for the delay in getting BESREMi® approved in the European Union, and the delay in bringing this important medication to the patients suffering from polycythaemia vera, a rare and chronic disease of the blood building cells”, explains Dr. Rudolf Widmann, Chief Therapeutics Officer, Member of the Board and founder of AOP Orphan. “We had initiated the arbitration already in March 2018, to appeal unfounded attempts by PharmaEssentia to terminate the contract, and for a damage compensation for delays caused by PharmaEssentia. Now we are reassured of our situation as the ICC ruled that the contract with PharmaEssentia is in full force and effect, and that AOP Orphan is entitled to damages of approximately EUR 143 million. Accordingly, we have issued an invoice to PEC on this amount for payment.” 3.心得/評論： AOP 開始跟公司要賠償金了 -- ※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 125.227.176.110 (臺灣) ※ 文章網址: https://www.ptt.cc/bbs/Stock/M.1603873682.A.D40.html

推

centaurjr

10/28 16:28, 3年前 , 1^F

10/28 16:28, 1^F

→

luche

10/28 16:35, 3年前 , 2^F

10/28 16:35, 2^F

→

melonQ

10/28 16:38, 3年前 , 3^F

10/28 16:38, 3^F